Boehringer Ingelheim agreed to invest $10 billion in U.S. pharmaceutical R&D and manufacturing through 2028 and to join the TrumpRx.gov direct‑purchase platform, under an arrangement that secures exemption from potential Section 232 tariffs. The company said part of the investment will expand U.S. manufacturing capacity and bolster supply‑chain resilience while offering discounted medicines to American patients. Jean‑Michel Boers, president and CEO of Boehringer Ingelheim USA, framed the pact as a patient‑access and investment initiative focused on chronic diseases. The deal highlights how U.S. industrial policy and pricing initiatives are shaping pharma investment and market access decisions.